Studies gene variants in people with multiple myeloma or MGUS
Checks gene changes in GBA and PSAP in adults with myeloma or MGUS.
Plain-language title generated from the registry record
Registry title: Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Key facts
- Where
- Rouen, FranceSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma or MGUS (a pre-myeloma blood condition). It checks how often changes occur in the GBA/PSAP genes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma: more than 10% tumour plasma cells in the bone marrow, a monoclonal peak in blood or urine, and organ damage from bone marrow invasion. MGUS: less than 10% plasma cells in the bone marrow, a monoclonal protein of less than 30g/L, and no clinical involvement.
- Biomarker or test result
- GBA/PSAP gene variants are measured in the trial; having one is not a condition to join.
Main reasons for not taking part
- Persons deprived of liberty by an administrative or judicial decision
- Persons under court protection, sub-guardianship or guardianship
- People not covered by a social security scheme
Read by machine on 12 November 2026.
Where in France
- Centre Henri BecquerelRouen, FranceContact: Fabrice FJ JARDIN, ProfessorNot yet recruiting
- University Rouen HospitalRouen, FranceContact: Gaétan GS SAUVETRE, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Rouen
- Trial code
- NCT06559033
- Record updated
- 10 June 2026
- Original description
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.Read full original descriptionShow less
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.
Inclusion: Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement); Membership of a social security scheme; Adult having read and understood the information letter and signed the consent form.
Exclusion: Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship.